FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the AISAP Cardio, a cloud-based, point-of-care ultrasound (POCUS) system that may enable early detection for a variety of cardiac conditions.1
Offering automated analyses and reports, the AISAP Cardio platform has four computer-assisted diagnosis (CAD) modules for valvular pathologies, according to AISAP, the developer of the POCUS system. Trained on over 24 million echocardiography video clips, the AISAP Cardio platform provides automated measurements for cardiac structural functional parameters, ranging from left ventricle ejection fraction (LVEF) and right ventricular fractional area change (RV FAC) to inferior vena cava (IVC) diameter.
AISAP notes that recently published prospective research showed that use of the AISAP Cardio platform led to management changes in one-third of patients.2 For clinicians with basic ultrasound skills, AISAP maintained that AISAP Cardio has up to a 90 percent accuracy rate in assessing common cardiac structural and functional parameters.1
Smadar Kort, M.D., said the AISAP Cardio platform, which will be commercially available on September 1, has “game-changer” potential.
“We know that structural heart disease and heart failure are the leading causes of hospitalization and morbidity in the U.S. Enabling a wide variety of qualified physicians to quickly and accurately diagnose these conditions at the bedside could lead to earlier detection and treatment, and better patient outcomes, as well as greater efficiencies and cost savings to health systems, while ultimately saving countless lives,” noted Dr. Kort, the system director of non-invasive cardiac imaging at Stony Brook Medicine in Stony Brook, N.Y.
References
1. AISAP. AISAP’s CARDIO AI-powered point-of-care ultrasound diagnostic assessment software receives FDA clearance. Business Wire. Available at: https://www.businesswire.com/news/home/20240822701346/en/AISAP%E2%80%99s-CARDIO-AI-powered-Point-of-Care-Ultrasound-Diagnostic-Assessment-Software-Receives-FDA-Clearance . Published August 22, 2024. Accessed August 22, 2024.
2. Fisher L, Yarkoni Y, Faierstein K, et al. Enhancing handheld point-of-care echocardiography with artificial intelligence: a prospective clinical trial. J Am Coll Cardio. 2024;83(13):2344.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
